Table of Contents  

Catheter-guided renal sympathetic denervation in patients with therapy-refractory hypertension

Georg Goliasch
Published in : HAMDAN MEDICAL JOURNAL ; Vol 5, No 1 (2012)
DOI : 10.7707/hmj.v5i1.110


Hypertension is the leading cause of cardiovascular disease worldwide, with a prevalence of 30–40% in the West and 20–35% in the Middle East. More than50% of patients have inadequate blood pressure control despite combined antihypertensive medication. Reasons for the failure to achieve recommended blood pressure values include lack of patient compliance and inefficiency of antihypertensive treatment (therapy-refractory hypertension).

View article in  :   HTML     PDF     Flip


Symplicity HTNI. Catheter-based renal sympathetic denervation for resistant hypertension: Durability of blood pressure reduction out to 24 months. Hypertension. 2011; 57:911–17.

Symplicity HTNI, Esler MD, Krum H, Sobotka PA, et al. Renal sympathetic denervation in patients with treatment-resistant hypertension (the symplicity htn-2 trial): a randomised controlled trial. Lancet. 2010;376:1903–9.

Add comment 

Home  Editorial Board  Search  Current Issue  Archive Issues  Announcements  Aims & Scope  About the Journal  How to Submit  Contact Us
Find out how to become a part of the HMJ  |   CLICK HERE >>
© Copyright 2012 - 2013 HMJ - HAMDAN Medical Journal. All Rights Reserved         Website Developed By Cedar Solutions INDIA